24/7 Patient Assistance: 760-405-8205

Omer Koc, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

Hospitals & Clinics

  • Bio & Insurance Information

    Dr. Omer Koc did his medical schooling at the Istanbul University Faculty of Medicine and later on did his residency at the Cleveland Clinic Foundation. He has also done a Fellowship at the Case Western Reserve University - University Hospitals. He is a board-certified medical oncologist and currently practices at the Cleveland Clinic Hospital.



  • Education & Training

    dept_icon

    Istanbul University Faculty of Medicine

    Medical School

    dept_icon

    Cleveland Clinic Foundation

    Residency

    dept_icon

    Case Western Reserve University - University Hospitals

    Fellowship

  • Board Certifications

    American Board of Internal Medicine

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    CLEVELAND CLINIC HOSPITAL

    Languages: English/Spanish

    (216) 445-0150

    9500 Euclid Ave Taussig Cancer Institute

    Cleveland, OH 44195

    Read More
  • Publications & Memberships

    Dr. Omer Koc has contributed to 3 publications.

    Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.

    Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W, Karp JE, Koc ON, Cooper BW, Luger...; Cancer Chemother. Pharmacol.. 2012-06-01.

    See more >>

    A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.

    Koç, O. N., Redfern, C., Wiernik, P. H., Rosenfelt, F., Winter, J. N., Carter, W. D., Gold, D. P., Stewart, M. E., Ghalie, R. G., Bender, J. F.; J Immunother. 2010-02-01.

    See more >>

    Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation

    Fu P, van Heeckeren WJ, Wadhwa PD, Bajor DJ, Creger RJ, Xu Z, Cooper BW, Laughlin MJ, Gerson SL, Koç ON, Lazarus HM; Contemp Clin Trials. 2008-03-01.

    See more >>